Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Calmangafodipir - Egetis Therapeutics

Next Previous
Drug Profile

Calmangafodipir - Egetis Therapeutics

Alternative Names: Aladote; PledOx; PP-095; PP-100; PP-100-01; SP-04 - Solasia Pharma

Latest Information Update: 28 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PledPharma
  • Developer Egetis Therapeutics; Solasia Pharma; University of Milan Bicocca
  • Class Acetates; Chemoprotectants; Ethylenediamines; Hepatoprotectants; Neuroprotectants; Pyridines; Small molecules
  • Mechanism of Action Antioxidants; Iron chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver failure
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chemotherapy-induced damage
  • Suspended Liver failure

Most Recent Events

  • 28 Nov 2024 No recent reports of development identified for preclinical development in Chemotherapy-induced-damage in China (IV, Infusion)
  • 17 Jul 2023 Preclinical trials in Chemotherapy-induced damage in Japan (IV) before July 2023 (Solasia Pharma pipeline, July 2023)
  • 05 Jul 2023 Egetis Therapeutics intends to submit NDA/MAA for Chemotherapy induced damage (Paracetamol poisoning) in 2025 (Egetis Therapeutics pipeline, July 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top